Kramer R A, Schuller H M, Smith A C, Boyd M R
J Pharmacol Exp Ther. 1985 Aug;234(2):498-506.
Administration of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1 1-nitrosourea (MeCCNU; 50-500 mg/kg) to male F344 rats caused a time- and dose-related decrease of glutathione (GSH) preferentially in the liver, but not in the kidney. A 500-mg/kg dose of MeCCNU decreased liver, lung and kidney GSH by 69, 15 and 3%, respectively, 2 hr after dosing. However, MeCCNU had no effect on the ratio of GSH/oxidized GSH or on GSH reductase activity in any tissue tested. A single i.p. dose of DL-buthionine-SR-sulfoximine, an inhibitor of GSH biosynthesis, caused tissue GSH levels to decrease at a rate which reflected the biological half-life of GSH in the respective organs. The T 1/2 for GSH in kidney, liver and lung was found to be 1.5, 5 and 9 hr, respectively. MeCCNU administered s.c. to DL-buthionine-SR-sulfoximine-pretreated rats resulted in a depletion of hepatic and renal GSH concentrations which was additive to the effects of either of these treatments alone. DL-Buthionine-SR-sulfoximine also markedly increased the nephrotoxicity of MeCCNU and resulted in a hepatotoxicity not ordinarily seen when MeCCNU was administered alone. These results suggest that a reactive electrophilic intermediate may be involved in the mechanism of MeCCNU nephrotoxicity. Moreover, that renal GSH may play a protective role against MeCCNU-induced nephrotoxicity.
给雄性F344大鼠腹腔注射1-(2-氯乙基)-3-(反式-4-甲基环己基)-1,1-亚硝基脲(MeCCNU;50 - 500毫克/千克)后,肝脏中的谷胱甘肽(GSH)出现了与时间和剂量相关的减少,而肾脏中则没有。给药后2小时,500毫克/千克剂量的MeCCNU使肝脏、肺和肾脏中的GSH分别降低了69%、15%和3%。然而,MeCCNU对任何测试组织中的GSH/氧化型GSH比值或GSH还原酶活性均无影响。单次腹腔注射GSH生物合成抑制剂DL-丁硫氨酸-SR-亚砜亚胺,会导致组织GSH水平以反映各器官中GSH生物学半衰期的速率下降。肾脏、肝脏和肺中GSH的半衰期分别为1.5小时、5小时和9小时。对经DL-丁硫氨酸-SR-亚砜亚胺预处理的大鼠皮下注射MeCCNU,导致肝脏和肾脏中GSH浓度降低,这是这两种处理单独作用效果的叠加。DL-丁硫氨酸-SR-亚砜亚胺还显著增加了MeCCNU的肾毒性,并导致了单独给予MeCCNU时通常不会出现的肝毒性。这些结果表明,一种活性亲电中间体可能参与了MeCCNU肾毒性的机制。此外,肾脏中的GSH可能对MeCCNU诱导的肾毒性起到保护作用。